Drug intelligence / Profile preview

BRD-03

Development stage: Unknown
Lead developer: Wuhan Boruida Biotechnology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

BRD-03 is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting B7-H3 (CD276), a transmembrane protein overexpressed in various solid tumors, including pediatric and adult sarcomas. Developed by Wuhan Boruida Biotechnology, BRD-03 is designed to recognize and eliminate tumor cells expressing B7-H3, which is associated with tumor progression and poor prognosis. The therapy is primarily being investigated for the treatment of recurrent or refractory bone and soft tissue sarcomas, such as osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma.

Other names: B7-H3 CAR-TB-7-H3 CAR-TB 7-H3 CAR-TCD276 CAR-TCD-276 CAR-TCD 276 CAR-T

Targets

B7-H3

Beyond the preview

Go deeper on BRD-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRD-03.

Explore the full profile